Literature DB >> 1933135

The cyclosporin-erythromycin interaction: impaired first pass metabolism in the pig.

D J Freeman1, D R Grant, S G Carruthers.   

Abstract

1. The pharmacokinetic interaction between cyclosporin (CsA) and erythromycin has been studied in the weanling pig model. 2. Blood CsA and metabolite-1 (M1) concentrations were monitored by high performance liquid chromatography in portal, hepatic and jugular venus blood before and after treatment with erythromycin stearate for 7 days. 3. Erythromycin significantly increased maximum concentration (Cmax) and area under the concentration-time curve from 0 to 24 h (AUC) of CsA in the peripheral circulation. This was accompanied by a significant reduction in the hepatic extraction ratio calculated from portal and hepatic Cmax and AUC data. 4. The extraction ratio appears to be concentration-dependent in that values derived from Cmax (high concentrations) were greater than those from AUC (average concentrations). 5. Time to Cmax (tmax) and t1/2 of CsA were essentially unchanged and no significant changes were observed in peripheral M1 kinetics apart from a small increase in tmax. 6. The pharmacokinetic changes observed in the pig suggest that the CsA-erythromycin interaction is caused by inhibition of hepatic metabolism and the impact of inhibition is greatest during first-pass when CsA concentrations are at their highest.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1933135      PMCID: PMC1907803          DOI: 10.1111/j.1476-5381.1991.tb09851.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Cyclosporine disposition in the hyperlipidemic rat model.

Authors:  L J Brunner; K Vadiei; D R Luke
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1988-03

2.  Erythromycin and cyclosporine.

Authors:  T A Gonwa; D D Nghiem; J A Schulak; R J Corry
Journal:  Transplantation       Date:  1986-06       Impact factor: 4.939

3.  Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient.

Authors:  N K Wadhwa; T J Schroeder; E O'Flaherty; A J Pesce; S A Myre; R Munda; M R First
Journal:  Ther Drug Monit       Date:  1987       Impact factor: 3.681

4.  The effects of erythromycin in patients treated with cyclosporine.

Authors:  R Martell; D Heinrichs; C R Stiller; M Jenner; P A Keown; J Dupre
Journal:  Ann Intern Med       Date:  1986-05       Impact factor: 25.391

5.  Inhibition of cyclosporine metabolism by other drugs in vitro.

Authors:  S Henricsson; A Lindholm
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

6.  Erythromycin enhances the absorption of cyclosporin.

Authors:  S K Gupta; A Bakran; R W Johnson; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

7.  Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay.

Authors:  S G Carruthers; D J Freeman; J C Koegler; W Howson; P A Keown; A Laupacis; C R Stiller
Journal:  Clin Chem       Date:  1983-01       Impact factor: 8.327

8.  Effect of erythromycin on cyclosporine levels.

Authors:  R J Ptachcinski; B J Carpenter; G J Burckart; R Venkataramanan; J T Rosenthal
Journal:  N Engl J Med       Date:  1985-11-28       Impact factor: 91.245

9.  Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

Authors:  T Kronbach; V Fischer; U A Meyer
Journal:  Clin Pharmacol Ther       Date:  1988-06       Impact factor: 6.875

10.  Effects of erythromycin on hepatic drug-metabolizing enzymes in humans.

Authors:  D Larrey; C Funck-Brentano; P Breil; J Vitaux; C Theodore; G Babany; D Pessayre
Journal:  Biochem Pharmacol       Date:  1983-03-15       Impact factor: 5.858

View more
  1 in total

1.  Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2'-methylguanosine-5'-monophosphate, in the monkey and formulation optimization for human exposure.

Authors:  Xin-Ru Pan-Zhou; Benjamin A Mayes; Hassan Rashidzadeh; Rahela Gasparac; Steven Smith; Sanjeev Bhadresa; Kusum Gupta; Marita Larsson Cohen; Charlie Bu; Steven S Good; Adel Moussa; Roger Rush
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-04-22       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.